SCHEMBL10292550

SCHEMBL10292550

CCc1nc2c(c(OC(C)C)c(C(=O)Nc3ccccn3)n2C)c(=O)n1Cc1cccc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.43
▸ PTGES O14684 3/20 0.42
▸ TP53 P04637 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CNR2 P34972 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ BRPF1 P55201 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ PTGER1 P34995 1/20 0.37
▸ P2RX3 P56373 1/20 0.36
▸ FAAH O00519 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ HTR7 P34969 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003686 0.90 PTGES (0.48) KMT2APTGESTP53ALDH1A1NPSR1
SCHEMBL10292840 0.89 PTGES (0.43) KMT2APTGESTP53ALDH1A1NPSR1
SCHEMBL11990834 0.87 PTGES (0.46) KMT2APTGESTP53ALDH1A1NPSR1
SCHEMBL10292461 0.87 KMT2A (0.43) KMT2APTGESALDH1A1NPSR1TSHR
SCHEMBL11990835 0.86 PTGES (0.46) KMT2APTGESTP53ALDH1A1NPSR1
SCHEMBL10292839 0.86 PTGES (0.46) KMT2APTGESTP53ALDH1A1NPSR1
SCHEMBL10004586 0.85 KMT2A (0.48) KMT2APTGESTP53ALDH1A1NPSR1
SCHEMBL10292542 0.85 KMT2A (0.44) KMT2APTGESTP53ALDH1A1NPSR1
SCHEMBL11990855 0.84 KMT2A (0.47) KMT2APTGESTP53ALDH1A1NPSR1
SCHEMBL10292545 0.84 KMT2A (0.43) KMT2APTGESTP53ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471793-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-10-05 — — EP disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
EP-2471793-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH KMT2A 423/4885PTGES 1468/4885TP53 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback